套细胞淋巴瘤治疗进展  

Progress in treatment of mantle cell lymphoma

作　　者：陆洛[1] 王莉[1] 徐卫[1] 

机构地区：[1]南京医科大学第一附属医院江苏省人民医院血液科,210029

出　　处：《白血病．淋巴瘤》2017年第3期148-151,共4页Journal of Leukemia & Lymphoma

摘　　要：套细胞淋巴瘤（MCL）是一种侵袭性的非霍奇金淋巴瘤（NHL）,占成年人NHL的6%～8%,常表现为淋巴结、胃肠道、骨髓等受累,虽最初治疗有效,但易复发或耐药.第58届美国血液学会年会关于MCL的研究涵盖了基础研究、临床治疗、新药研究等多个方面,一些新动物模型的建立、信号通路靶点的研究为完善MCL发病机制及新药研究提供了基础;VcR-CVAD、VCR方案及对于年轻、 老年患者治疗新方案的尝试都取得了不错的效果;周期蛋白依赖性激酶（CDK）抑制剂、 磷脂酰肌醇3激酶（PI3K）抑制剂、bcl-2抑制剂等新型药物在初期临床试验中也显示出令人欣喜的结果,IACS-010759等小分子的出现为MCL治疗提供了新方向.Mantle cell lymphoma （MCL）, being a kind of aggressive non-Hodgkin ＇ s lymphoma （NHL）, accounts for 6 % - 8 % of NHL in adults which is characterized by malignant B cell infiltration of lymph node, gastrointestinal tract and bone marrow. MCL commonly responds to initial therapy but inevitably occurs relapse and drug resistance. The study on MCL in the 58th American Society of Hematology Annual Meeting has covered many aspects such as basic research, clinical treatment and new drug research. The development of novel mouse model and the exploration of signaling pathways provide a basis for the improvement of MCL pathogenesis and new drug research. VcR-CVAD, VCR and some other chemotherapy regimens designed for different patients have showed satisfactory results. New drugs such as inhibitors of CDK, PI3K and bcl-2 in initial clinical trials are also promising. IACS-010759 and other small molecules provide new directions for the treatment of MCL.

关 键 词：套细胞淋巴瘤 美国血液学年会 

分 类 号：R733.1[医药卫生—肿瘤]